Abstract

PURPOSE OF INVESTIGATION
To assess the clinical relevance of serum growth-regulated oncogene alpha (GROalpha) levels in gynecological cancer, we investigated its concentration in distinguishing patients with cervical cancer, endometrial cancer, ovarian cancer, benign ovarian tumor and control.
METHODS
Preoperative serum GROalpha levels were measured in women with cervical cancer (n=46), endometrial cancer (n=39), ovarian cancer (n=124), benign ovarian tumors (n=52), and normal controls (n=38) using an enzyme-linked immunosorbent assay.
RESULTS
Statistical analyses showed that the serum GROalpha concentration was significantly elevated in the cervical cancer, endometrial cancer and ovarian cancer patients compared with controls. Using GROalpha levels, the receiver operating characteristic (ROC) of cervical cancer (AUC approximately 0.775), endometrial cancer (AUC approximately 0.799), ovarian cancer (AUC approximately 0.749) and benign ovarian tumors (AUC approximately 0.568) vs. controls were identified.
CONCLUSION
Our findings suggest that serum GROalpha measurement as a molecular marker might contribute to detection and diagnosis of gynecological cancer.

Authors

Nishikawa R, Suzumori N, Nishiyama T, Nishikawa H, Arakawa A, Sugiura-Ogasawara M

Institution

Department of Obstetrics and Gynecology, Nagoya City University, Graduate School of Medicine, Japan.

Source

European journal of gynaecological oncology 33:2 2012 pg 138-41

MeSH

Adenocarcinoma, Clear Cell
Adenocarcinoma, Mucinous
Area Under Curve
Carcinoma
Carcinoma, Endometrioid
Chemokine CXCL1
Enzyme-Linked Immunosorbent Assay
Female
Humans
Logistic Models
Middle Aged
Ovarian Cysts
Ovarian Neoplasms
ROC Curve
Statistics, Nonparametric
Tumor Markers, Biological
Uterine Cervical Neoplasms

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22611950